Polifarma İlaç Among Turkey's Top 500 Industrial Enterprises

Polifarma has been included in the ISO (Istanbul Chamber of Industry) First 500 List according to the 2022 results of the Turkey's 500 Largest Industrial Enterprises Survey conducted by ISO. For 37 years with 100 percent domestic capital, Polifarma has been one of Turkey's leading organizations in the healthcare sector, providing valuable contributions to public health and the health sector. The company has demonstrated success in entering the ranks of Turkey's 500 largest industrial enterprises and has further solidified its leadership position in the sector. Polifarma İlaç's net sales from production, which is the main size criterion for companies eligible for the 2022 ISO First 500 List, amounted to TRY 2,291,056,499. Since its establishment, Polifarma has operated with the belief that health is a fundamental human right. Embracing quality, reliability and innovation, the company works through a wide range of products to reduce Turkey's external dependence and ensure easy access to medicines. Exporting to more than 70 countries, Polifarma is Turkey's most preferred brand in serum and hospital products. Polifarma İlaç manufactures medicines for many therapeutic areas including anesthesia, intensive care, infection, oncology, radiology, dialysis and cardiology, as well as critical serums. The company has approximately 600 licensed products in vial, bottle and PFS forms. In addition to being among Turkey's leading healthcare organizations, Polifarma has also made a name for itself abroad, playing an active role on the global stage. The company draws attention with the importance it places on research and development activities and investments while monitoring innovations in the health sector. Polifarma's 11,000 m² production facility located in Tekirdağ – Ergene district, which was recently laid out and is planned to be completed and operational in the first months of 2024, will be one of the country's most functional research and development centers in terms of design and efficiency. The new production unit, where orphan drugs that Polifarma is developing as the world's first generic and other biotechnology medicines will be produced, will feature research and development laboratories, technical departments, management offices and training and seminar areas. The facility is aimed at increasing drug development capacity with 300 scientists.